Skip to content
Live funding
Sesame Summit 2027
Sesamers

IntelliProve raises €2.7M seed to take its face scan to robots

A Ghent team that reads heart rate and blood pressure from a face scan spends a third of its €2.7M seed on certification before it takes the scan to humanoid robots.

Also see more funding coverage: /funding/

Round at a glance
€2.7MSeed Announced 19 November 2026
Belgium
CompanyIntelliProve · profile
HQBelgium
StageSeed

IntelliProve, a Ghent company that reads vital signs from a camera feed, raised €2.7M in seed funding led by Miles Ahead, with Wit-Gele Kruis, the imec.istart Fund and several business angels joining, to take its face scan from smartphones to humanoid robots.

Medical software in Europe lives or dies on certification, and a seed round in Flanders shows how one small team plans to pay for that. Below, I lay out the round, the company, the market numbers, and the pattern I see in where the money goes.

Get the Weekly brief

The week’s rounds, last calls and events, every Monday.

Miles Ahead leads a €2.7M seed in Ghent

IntelliProve announced the €2.7M seed round on November 19, according to The Next Web. Miles Ahead led it. Wit-Gele Kruis, the Flemish home nursing organization, took part alongside the imec.istart Fund and several business angels the company did not name.

Co-CEO Joeri Tulkens told The Next Web that the money splits into roughly three parts: about a third for regulatory work, a third for further research, and a third for commercial growth, including robotics deployments. The company also plans to collect more data across skin tones, ages, lighting conditions and devices, and to pursue certification beyond Europe. In Tulkens’s words, the ambition is “a health sensing layer that care can rely on, on any camera.”

Thirty seconds, one camera, four vital signs

IntelliProve builds software that estimates heart rate, heart rate variability, breathing and blood pressure from a 30-second scan of a face, using a standard camera and no cuff. The technique is called remote photoplethysmography, and the company trained its own deep learning model for blood pressure. Care providers, insurers and wellbeing platforms in more than 50 countries embed the scan in their apps, according to the company.

The regulatory record is specific. The core signal acquisition engine carries a CE mark as a Class I medical device under the EU Medical Device Regulation, and the team is working toward Class IIa. In its own tests, 97.6% of heart rate readings landed within five beats per minute of a reference device, as reported by The Next Web. Partners include TU Delft and Ghent University Hospital. Tech.eu reported a €1.25M raise for the company in January 2025, and this round follows it.

A small market with two very different growth rates

Sizing this segment depends on where you draw the line. Straits Research puts non-contact vital signs detectors, a medical device category that spans radar, camera, thermal and radio frequency sensing, at USD 327.36 million in 2025 and USD 730.00 million by 2034, a 9.32% CAGR over 2026-2034 (report page updated November 19, 2026). Roots Analysis looks only at AI-powered camera systems and sees USD 2.2 billion in 2026 growing to USD 18.8 billion by 2040, a 16.6% CAGR. Neither report is a measurement of IntelliProve’s own niche, and the gap between them tells you the definition is still fluid.

Our own records give the amount some scale. Agora Labs, a clinical AI company, raised €4.3M on October 28. Scarlet, which certifies AI medical devices, raised a $50M Series B on October 12. A €2.7M seed sits below the first and is a small fraction of the second. At that size, a 9% to 17% market growth rate gives a company a tailwind and no guarantee. Certification and distribution decide the outcome.

Regulation as a line in the budget

The reality is that a camera-based vital signs claim needs clinical evidence before a hospital buyer takes it seriously, and that evidence takes time and money. The silver lining is that Europe has a legible path: Class I today, Class IIa next, with named academic and hospital partners in Ghent and Delft. IntelliProve budgets a third of its seed for exactly that work, and Scarlet’s $50M Series B shows the size of check that certification-focused companies can attract.

The robot angle is the unproven part. Humanoid robotics funding is running hot, and the company says it already works with unnamed robotics partners. Imagine if a care robot in a Flemish nursing home read a resident’s blood pressure from across the room, with a CE mark behind the number. What to watch is whether those partners get named, and whether the Class IIa decision arrives before the next round.

Every round we track is on the fundraising data desk. The pattern here is clear enough. A Ghent team is spending its first real money on proof, and proof is what turns a clever scan into infrastructure. Let’s watch the Class IIa decision!

Get the weekly briefing Europe's rounds, founders & events - every Monday, in five minutes.